Metabolic abnormalities and body fat redistribution in HIV-1 infected patients: The lipodystrophy syndrome

Current Opinion in Infectious Diseases

Volumn 12, Issue 1, 1999, Pages 13-19

  Martínez, Esteban ^a   Gatell, José M ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; ATORVASTATIN; CHOLESTEROL; GEMFIBROZIL; HUMAN GROWTH HORMONE; INDINAVIR; INSULIN; PROTEINASE INHIBITOR; RITONAVIR; TROGLITAZONE;

BODY FAT; CLINICAL FEATURE; DIABETES MELLITUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERCHOLESTEROLEMIA; HYPERLIPIDEMIA; INSULIN RESISTANCE; LIPODYSTROPHY; METABOLIC DISORDER; OBESITY; PATHOGENESIS; REVIEW; SUBCUTANEOUS DRUG ADMINISTRATION; WASTING SYNDROME;

EID: 0032968965     PISSN: 09517375     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001432-199902000-00003     Document Type: Review

References (63)

1. Palella FJ, Delaney KM, Moorman AC, Loveless MD, Fuhrer J, Satten GA, et al. •• Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338: 853-860. This study nicely shows how the introduction of protease inhibitors has resulted in an unprecedented decline in the morbidity and the mortality of HIV-1 infected patients.
2. ••].
3. Wong JK, Hazareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, •• Richman DD. Recovery of replication-competent HIV despite prolonged suppression of HIV viremia. Science 1997; 278: 1211-1215. Both studies showed that long-lived CD4 lymphocytes carrying replication-competent HIV-1 particles had been recovered from patients after 2 years of suppressive therapy.
4. ••]
5. ••].
6. Pialoux G, Raffi F, Brun-Vezinet F, Meiffrédy V, Flandre P, Gastaut JA, et al. A •• randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1 infected patients. N Engl J Med 1998, 339: 1269-1276 These three studies explored the concept of induction antiretroviral therapy followed by maintenance therapy. After 3-6 months of suppressive antiretroviral therapy, all these studies showed that maintenace therapy was less effective in sustaining a reduced viral load than continuing induction therapy.
7. •].
8. Hirsch MS, Klibanski A. What price progress? Pseudo-Cushing's syndrome • associated with antiretroviral therapy in patients with human immunodeficiency virus infection Clin Infect Dis 1998; 27: 73-75 These editonals comment on the recently described issue of lipodystrophy and raise questions about the epidemiology, aetiology, and implications of this problem.
9. Kotler DP, Rosenbaum KB, Wang J, Pierson RN Jr. Alterations in body fat distribution in HIV-infected men and women. 12SP>/SP> World Conference on AIDS, Geneve 1998: abstract 32173.
10. Engelson ES, Kotler DP, Tan YX, Agin D, Bashist B, Wang J, Heymsfield SB. Altered body fat distribution in HIV infection: Regional body composition measurements by whole body MRI and DXA scans 12th World Conference on AIDS, Geneve 1998: abstract 32181
11. Lo JC, Mulligan K, Tai VW, Algren H, Schambelan. 'Buffalo hump' in men with •• HIV-1 infection. Lancet 1998, 351. 867-870 This is the first published report on abnormal fat deposition at the back of the neck in HIV-1 infected patients. These authors excluded hypercortisolism as the aetiology of the clinical picture despite resemblance with Cushing's syndrome Four of eight patients described had never taken protease inhibitors.
12. Stricker RB, Goldberg B. Weight gain associated with protease inhibitor • therapy in HIV-infected patients. Res Virol 1998; 149: 123-126. Ten consecutive HIV-1 infected patients who were treated with protease inhibitors showed an increase in weight after 6 months of therapy. Weight increase was not correlated with CD4 cell variation The authors hypothesised that the anabolic effects of these protease inhibitors would be caused not by their antiretroviral properties, but by the blockade of the degrading enzymes of several anabolic hormones.
13. Carbonnel F, Maslo C, Beaugerie L, Carrat F, Wirbel E, Aussel C, et al. Effect of •• indinavir on HIV-related wasting AIDS 1998; 12: 1777-1784. Sixteen patients with wasting were followed for 6 months. Body weight increased significantly and it was correlated with changes in the CD4 cell count and the viral load.
14. Walli R, Herfort O, Michl GM, Demant T, Jäger H, Dieterle C, et al. Treatment •• with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1-infected patients AIDS 1998; 12: F167-F173 This study shows that the treatment with protease inhibitors is associated with insulin resistance, leading to impaired or diabetic oral glucose tolerance in some patients, and with hyperlipidaemia.
15. Martinez E, Casamitjana R, Conget I, Gatell JM. Protease inhibitor-associated •• hyperinsulinaemia. AIDS 1998; 12: 2077-2079. This study clearly shows that short-term therapy with protease inhibitors is associated with insulin resistance and hyperlipidaemia. Hyperinsulinaemia was mainly caused by reduced insulin clearance
16. Viraben R, Aquilina C Indinavir-associated lipodystrophy. AIDS 1998; 12: F37-• F39. This article describes the loss of subcutaneous fat tissue in a group of patients on HAART including indinavir from the dermatologist' point of view. Fat wasting appeared after a median follow-up of 8.5 months (range: 2-12) Patients also showed hyperinsulinaemia
17. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein Y, Fallon J. Visceral •• abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351: 871-575. This is the first published report on the development of central obesity in HIV-1 infected patients treated with protease inhibitors Abdominal fat was measured with computed tomography. In this study, the visceral fat accumulation was associated with hypertriglyceridemia.
18. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA. A •• syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS 1998; 12: F51-F58. This may be the most comprehensive study to date on the metabolic abnormalities and lipodystrophy associated with protease inhibitor therapy. It is a cross-sectional study, but provides insight into the prevalence of diabetes mellitus and lipodystrophy with different protease inhibitor regimens.
19. Norvir package insert. Abbot Laboratories, North Chicago, IL, USA. May, 1996
20. Dong K, Flynn MM, Dickinson BP, Rich JD, Tashima K, Flanigan TP, Carpenter CCJ Changes in body habitus in HIV(+) women after initiation of protease inhibitor therapy. 12th World AIDS Conference. Geneve 1998: abstract 12373.
21. Bernasconi E, Carota A, Magenta L, Pons M, Russotti M, Moccetti T. Metabolic changes in HIV-infected patients treated with protease inhibitors. 12th World AIDS Conference. Geneva 1998: abstract 12375.
22. Pollner J, Aronson EN, McHugh S, Nielson R, Hawkes C. Significant increases in serum cholesterol are seen among HIV patients taking protease inhibitors. 12th World AIDS Conference. Geneva 1998: abstract 12269.
23. Lumpkin MM. Reports of diabetes and hyperglycemia in patients receiving • protease inhibitors for the treatment of human immunodeficiency virus (HIV). FDA Public Health Advisory, June 1997. This was the first report warning on the possibility of an increased risk of diabetes and hyperglycaemia in HIV-1 infected patients treated with protease inhibitors.
24. Dube MP, Johnson DL, Currier JS, Leedom JM. Protease inhibitor-associated •• hyperglycaemia. Lancet 1997; 350: 713-714. Protease inhibitors can be associated with a type 2 diabetes mellitus. The incidence of diabetes mellitus in HIV-1 infected patients treated with protease inhibitors is <%. Some patients described had to discontinue protease inhibitors to control hyperglycaemia.
25. Dever LL, et al. Hyperglycemia associated with protease inhibitors in HIV-infected patients. 37th ICAAC, Toronto, Ontario, Canada, 1997: abstract LB-8.
26. •].
27. Eastone JA, Decker CF. New-onset diabetes mellitus associated with use of • protease inhibitor. Ann Intern Med 1997, 127. 948 These two letters reported anecdotal cases of HIV-1 infected patients who developed diabetes mellitus in association with protease inhibitor therapy.
28. Keruly JC, Chaisson RE, Moore RD. Diabetes and hyperglycemia in patients receiving protease inhibitors. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, 1998: abstract 415.
29. Dong BJ, Gruta C, Legg J, Balano K, Goldschmit. Diabetes and use of protease inhibitors. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, illinois, 1998: abstract 416.
30. Caldwell R, Rothstein A, Allmon C, Montoya JG, Zolopa A. Evaluation of protease inhibitor-associated hyperglycemia in a university-based HIV clinic. 12th World Conference on AIDS, Geneva 1998: abstract 12395.
31. Flexner C. HIV-protease inhibitors. N Engl J Med 1998; 338: 1281-1292 •• This is the most comprehensive review on protease inhibitors to date. Lipodystrophy in association with protease inhibitors is recognized for the first time in a review on protease inhibitors.
32. Rosenberg HE, Mulder J, Sepkowitz KA, Giordano MF. 'Protease-paunch' in HIV+ persons receiving protease inhibitor therapy: incidence, risks and endocrinologic evaluation. 5th Conference on Retroviruses and Opportunistic Infections. Chicago, Illinois, 1998: abstract 408
33. Herry I, Bernard L, de Truchis P, Peronne C. Hypertrophy of the breasts in a • patient treated with indinavir. Clin Infect Dis 1997; 25: 937-938. This is the first report on increase in breast size in women treated with a protease inhibitor.
34. Ruane PJ Atypical accumulation of fatty tissue. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy 1997: 1-185.
35. Hengel RL, Watts NB, Lennox JL. Benign symmetric lipomatosis associated • with protease inhibitors Lancet 1997; 350: 1596. Description of an HIV-1 infected patient with atypical fat deposition in the neck and shoulders. Cushing's syndrome was excluded with a low-dose dexamethasone suppression test.
36. ••].
37. ••].
38. Striker R, Conlin D, Marx M, Wiviott L Localized adipose tissue hypertrophy in •• patients receiving human immunodeficiency virus protease inhibitors. Clin Infect Dis 1998; 27. 218-220. These three articles describe 13 HIV-1 infected patients who developed atypical dorsocervical and, in some instances, submandibular fat accumulation and central obesity after a median of 4-6 months of protease inhibitor therapy. In some patients, the fat mass was removed and pathological examination disclosed unremarkable adipose tissue. Cushing's syndrome was excluded in the Miller et al. study. No regression was observed after protease inhibitor discontinuation at short-term (<3 months).
39. Boix V, Reus S, Priego M, Merino E, Roman F, Climent E, Portilla J. Expanding the spectrum of protease inhibitors-induced lipodistrophy 12th World AIDS Conference. Geneva 1998; abstract 12398.
40. Carr A A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. 12th World AIDS Conference. Geneva 1998: abstract LB8.
41. Wong KH, Ho TY, Chan CW, Wong KH, Lee SS. Indinavir-associated facial atrophy in HIV positive patients. 12th World AIDS Conference. Geneva 1998. abstract 12391.
42. Veny A, Bonjoch A, Romeu J, Balague J, Johnston J, Sirera G, et al. Cummulative risk for developing protease inhibitor-associated lipodystrophy. 38th ICAAC, San Diego, California, 1998: abstract 1-92.
43. De Luca A, Murri R, Darmiano F, Ammasan A, Antinon A. 'Buffalo hump' in HIV-1 • infection. Lancet 1998, 352: 320. This article provides information on the prevalence of lipodystrophy (25%) in a group of patients exposed to protease inhibitors a median of 6 months. Lipodistrophy developed in patients taking every one of the currently marketed protease inhibitors
44. Sellmeyer DE, Grunfeld C. Endocrine and metabolic disturbances in human • immunodeficiency virus infection and the acquired immune deficiency syndrome. Endocr Rev 1996; 17. 518-532
45. ••].
46. ••]
47. Stricker RB, Goldberg B Fat accumulation and HIV-1 protease inhibitors. •• Lancet 1998; 352: 1392. These three articles speculate on the potential pathogenetic mechanisms for those metabolic abnormalities seen in HIV-1 infected patients treated with protease inhibitors. All three hypotheses coincide that Pls are not specific of the HIV-1 protease and may inhibit some human protein(s) involved in lipid and carbohydrate metabolism.
48. ••]) on the pathogenesis of protease inhibitor-associated metabolic abnormalities.
49. Gagnon AM, Angel JB, Sorisky A Protease inhibitors and adipocyte • differentiation in cell culture. Lancet 1998; 352: 1032. This report describes that protease inhibitors have an estimulatory effect on adipogenesis in cell cultures.
50. Poorman RA, Tomasselli AG, Heinnkson RL, Kézdy FJ A cumulative specificity model for proteases from human immunodeficiency virus types 1 and 2, inferred from statistical analysis of an extended substrate data base. J Biol Chem 1991, 266: 14554-14561.
51. Arner P. All fat is not alike. Lancet 1998; 351: 1301-1302. • This editorial reminds us of the differences between visceral and subcutaneous fat tissue. Although not directly addressed to that issue, this note may give useful insight on the pathogenesis of protease inhibitor-associated lipodystrophy.
52. Ruderman N, Chisholm D, Pi-Sunyer X, Schneider S. The metabolically obese, •• normal-weight individual revisited. Diabetes 1998; 47: 699-713. This review on the topic of the metabolically obese, normal-weight individual may be very helpful for considering protease inhibitor-associated lipodystrophy, as some manifestations of the latter are very similar to those of the medically obese, normal-weight individuals. The authors raise the question of whether central obesity could be the result of insulin resistance or a concurrent event rather than its cause
53. Duncombe C, Bloch M, Austin D, Quan D. Reversal of hyperlipidaemia and lipodystrophy in patients switching therapy to nelfinavir 12th World AIDS Conference, Geneve 1998: abstract 12287.
54. Dube MP, Johnson DLJ, Currier JSC, Leedom JML. Protease inhibitor-associated hyperglycemia. Results of switching from indinavir to nelfinavir. 12th World AIDS Conference, Geneva 1998: abstract 32172.
55. Martinez E, Lozano L, Conget I, Casamitjana R, Gatell J Reversion of lipodystrophy after switching from HIV-1 protease inhibitors to nevirapine. 6th Conference on Retroviruses and Opportunistic Infections, Chicago, IL, 1998: abstract 670.
56. •].
57. •].
58. •].
59. •]
60. Stocker DN, Merer PJ, Stoller R, Fattinger KE "Buffalo hump" in HIV-1 • infection. Lancet 1998; 352: 320-321 These authors described anecdotal cases of coronary disease in young adult HIV-1 infected patients who had metabolic abnormalities after starting protease inhibitor therapy. Although these results cannot be generalized at present, serious concern exists that HIV-1 infected patients with metabolic abnormalities may be at a high cardiovascular risk in the near future.
61. Hewitt RG, Shelton MJ, Esch LD. Gemfibrozil effectively lowers protease inhibitor-associated hypertriglyceridemia in HIV-1 positive patients. 38th ICAAC, San Diego, California. 1998: 64-1.
62. •] showed that gemfibrozil and/or atorvastatin effectively reduced hyperlipidaemia in adult HIV-1 infected patients treated with protease inhibitors. However, it is not known if such a positive effect may translate into a beneficial effect on the protease inhibitor-associated lipodystrophy.
63. Torres R. Treatment of dorsocervical fat pads and truncal adiposity with serostim (recombinant human growth hormone) in patients with AIDS maintained on HAART. 12th World Conference on AIDS, Geneva 1998: abstract 32164.